Nuveen
KNSA icon

Nuveen’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Nuveen’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.14M Buy
127,255
+100,307
+372% +$5.2M ﹤0.01% 1824
2026
Q1 		$1.3M Buy
26,948
+6,715
+33% +$297K ﹤0.01% 2467
2025
Q4 		$835K Hold
20,233
– – ﹤0.01% 2692
2025
Q3 		$786K Buy
+20,233
New +$657K ﹤0.01% 2730
2025
Q2 		– Sell
-765,054
Closed -$17M – 3335
2025
Q1 		$17M Sell
765,054
-30,558
-4% -$629K 0.01% 1228
2024
Q4 		$15.7M Buy
795,612
+54,361
+7% +$1.24M ﹤0.01% 1317
2024
Q3 		$18.5M Sell
741,251
-25,160
-3% -$613K 0.01% 1246
2024
Q2 		$14.3M Sell
766,411
-64,688
-8% -$1.21M ﹤0.01% 1350
2024
Q1 		$16.4M Buy
831,099
+420,075
+102% +$8.2M ﹤0.01% 1302
2023
Q4 		$7.21M Sell
411,024
-152,902
-27% -$2.51M ﹤0.01% 1776
2023
Q3 		$9.8M Buy
563,926
+450,181
+396% +$7.58M ﹤0.01% 1498
2023
Q2 		$1.6M Hold
113,745
– – ﹤0.01% 2456
2023
Q1 		$1.22M Sell
113,745
-40,573
-26% -$535K ﹤0.01% 2536
2022
Q4 		$2.31M Buy
154,318
+50,931
+49% +$742K ﹤0.01% 2321
2022
Q3 		$1.33M Sell
103,387
-4,767
-4% -$54.3K ﹤0.01% 2608
2022
Q2 		$1.05M Buy
108,154
+14,176
+15% +$132K ﹤0.01% 2757
2022
Q1 		$966K Sell
93,978
-13,331
-12% -$141K ﹤0.01% 2826
2021
Q4 		$1.26M Buy
107,309
+4,493
+4% +$55.2K ﹤0.01% 2771
2021
Q3 		$1.25M Sell
102,816
-670
-0.6% -$8.72K ﹤0.01% 2899
2021
Q2 		$1.44M Buy
103,486
+11,543
+13% +$175K ﹤0.01% 2858
2021
Q1 		$1.7M Sell
91,943
-337,060
-79% -$6.89M ﹤0.01% 2691
2020
Q4 		$7.58M Sell
429,003
-15,626
-4% -$274K ﹤0.01% 1870
2020
Q3 		$6.81M Buy
444,629
+115,527
+35% +$2.17M ﹤0.01% 1751
2020
Q2 		$8.39M Buy
329,102
+62,915
+24% +$1.31M ﹤0.01% 1602
2020
Q1 		$4.12M Buy
266,187
+229,217
+620% +$3.59M ﹤0.01% 1828
2019
Q4 		$409K Sell
36,970
-3,770
-9% -$32.8K ﹤0.01% 2949
2019
Q3 		$347K Buy
40,740
+2,251
+6% +$24.9K ﹤0.01% 3029
2019
Q2 		$521K Buy
+38,489
New +$597K ﹤0.01% 2994

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Nuveen's KNSA Position: Q2 2026 in Review

Nuveen increased its Kiniksa Pharmaceuticals (KNSA) stake by 372% in Q2 2026, buying an estimated $5.2M and bringing the position to 127,255 shares worth $8.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1824.

Nuveen first reported a position in KNSA in Q2 2019 and has held it in 28 quarters since. The position peaked at $18.5M in Q3 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Nuveen held 127,255 shares of Kiniksa Pharmaceuticals worth $8.14M as of Q2 2026.
  • Nuveen bought 100,307 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $5.2M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1824 holding.
  • Nuveen first reported a position in Kiniksa Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Kiniksa Pharmaceuticals position peaked at $18.5M in Q3 2024.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.